Pharmacogenomics Market by Technology (Sequencing, Polymerase Chain Reaction, Gel Electrophoresis, Mass Spectrometry, Microarray, and Others), Application (Cardiovascular Diseases, Infectious Diseases, Oncology, Neurological Diseases, Psychiatry, Pain Management, and Others), and End User (Hospitals & Clinics, Research Institutions and Academic Institutes and Others): Opportunity Analysis and Industry Forecast, 2017 - 2025

 The global pharmacogenomics market generated $5,312.8 million in 2017 and is projected to reach $10,265.5 million by 2025, growing at a CAGR of 8.61% from 2018 to 2025. Pharmacogenomics is the field of science that evaluates the genetic makeup of an individual that affects the response to drugs. Pharmacogenomics combines the knowledge of pharmacology and genomics. It deals with the interaction of genetic variation and its influence over the drug response in patients by correlating genetic expression and its variability leading to drug's efficacy or toxicity.

There has been a surge in demand for the use of pharmacogenomics as a tool to customize and optimize drug therapy to suit the patients' genomic profile ensuring maximum efficacy and minimal adverse effects. Pharmacogenomics is a branch which studies the correlation between the genomic profile of the patient and the effects of drug over it. Pharmacogenomics belongs to the field of personalized medicine that promises the development of pharmacogenomics-based diagnostics tests in which drugs and drug combinations are optimized suiting the individual genotype. Pharmacogenomics is a field of science dealing with the identification of single nucleotide polymorphism in the interspecies and the effects it has over the drug diagnosis test that is used to identify the best suited drug, which is expected to not have an adverse effect on the patient and help the drug act effectively on the target. There is an increase in the demand for pharmacogenomics-based drug discovery and diagnostics owing to growth in prevalence of cancer, drug recalls, surge in awareness of pharmacogenomics diagnosis for treatment of cancer, higher number of R&D studies, and rise in adoption of pharmacogenomics in the development of drugs for pain management with better efficacy. Government initiatives and huge investments by private companies in R&D drive the pharmacogenomics market. Furthermore, surge in the aging population and rise in the global incidences of cancer are anticipated to boost the market growth. The application of high throughput genomic technologies in biomedical research and therapeutic procedures accelerate the market progression.

The global pharmacogenomics market is segmented based on technology, application, end user, and region. Based on technology, the market is segregated as polymerase chain reaction, microarray, sequencing techniques, mass spectrometry and electrophoresis. Based on application, the pharmacogenomics market is further categorized into cancer, cardiovascular diseases, infectious diseases, neurological diseases and pain management among others. Based on end user, it is segmented as hospitals & clinics, research institutions and academic institutes. Based on region, the market is studied across North America (U.S., Canada, and Mexico), Europe (Germany, France, the UK, and rest of Europe), Asia-Pacific (China, Japan, Australia, India, and rest of Asia-Pacific), and LAMEA (Brazil, and rest of LAMEA).

KEY MARKET BENEFITS

• The study provides an in-depth analysis of the global pharmacogenomics market share along with the current trends and future estimations to elucidate the imminent investment pockets.

• The report presents a quantitative analysis of the market to enable stakeholders to capitalize on the prevailing market opportunities.

• An extensive analysis of the market based on application assists in understanding the trends in the industry.

• The key market players along with their strategies are thoroughly analyzed to understand the competitive outlook of the industry.

KEY MARKET SEGMENTS

Market by Technology

o Polymerase Chain Reaction

o Microarray

o Sequencing

o Mass Spectrometry

o Electrophoresis

o Others

Market by Application

o Oncology

o Infectious diseases

o Cardiovascular diseases

o Neurological diseases

o Psychiatry

o Pain management

o Others

By End User

o Hospitals and clinics

o Research institutions

o Academic institutes

By Region

• North America

o U.S.

o Canada

o Mexico

• Europe

o Germany

o France

o UK

o Rest of Europe

• Asia-Pacific

o Japan

o China

o India

o Australia

o Rest of Asia-Pacific

• LAMEA

o Brazil

o Rest of LAMEA

The list of key players operating in this market includes:

• Abbott Laboratories

• Admera Health

• Dynamic DNA Laboratories

• Empire Genomics, LLC

• F. Hoffmann-La Roche Ltd.

• Illumina, Inc

• OneOme, LLC

• Myriad Genetics Inc

• OPKO Health, Inc (GeneDx.)

• Thermo Fisher Scientific, Inc

The other players included in the value chain analysis (and not included in the report) include:

• Teva Pharmaceutical Industries Ltd.

• Assurex Health Inc.

• Admera Health

• Bayer A

Chapter: 1: INTRODUCTION

1.1. Report description

1.2. Key benefits for stakeholders

1.3. Key market segments

1.4. Research methodology

1.4.1. Secondary research

1.4.2. Primary research

1.4.3. Analyst tools & models

Chapter: 2: EXECUTIVE SUMMARY

2.1. Key findings of the study

2.2. CXO Perspective

Chapter: 3: MARKET OVERVIEW

3.1. Market definition and scope

3.2. Key findings

3.2.1. Top investment pockets

3.3. Porter’s five forces analysis

3.4. Market dynamics

3.4.1. Drivers

3.4.1.1. Growing demand for personalized therapy

3.4.1.2. Increased prevalence of life-threatening diseases worldwide

3.4.1.3. Technological advancements in the molecular techniques used for pharmacogenomics-based diagnostics

3.4.2. Restraints

3.4.2.1. Dearth of well-trained and technically skilled professionals

3.4.2.2. Complexities in finding the right gene affecting the drug response

3.4.3. Opportunity

3.4.3.1. Technological advancements in molecular techniques used for pharmacogenomics diagnostic tests

3.4.3.2. Lucrative opportunities in the emerging economies

3.5. Top Player Positioning, 2017

Chapter: 4: GLOBAL PHARMACOGENOMICS MARKET, BY TECHNOLOGY

4.1. Overview

4.1.1. Market size and forecast

4.2. Next Generation Sequencing

4.2.1. Key market trends and growth opportunities

4.2.2. Market Size and forecast

4.3. Polymerase Chain Reaction

4.3.1. Key market trends and growth opportunities

4.3.2. Market Size and forecast

4.4. Gel electrophoresis

4.4.1. Key market trends and growth opportunities

4.4.2. Market Size and forecast

4.5. Mass Spectrometry

4.5.1. Key market trends and growth opportunities

4.5.2. Market Size and forecast

4.6. Microarray

4.6.1. Key market trends and growth opportunities

4.6.2. Market Size and forecast

4.7. Others

4.7.1. Key market trends and growth opportunities

4.7.2. Market Size and forecast

Chapter: 5: GLOBAL PHARMACOGENOMICS MARKET, BY APPLICATION

5.1. Overview

5.1.1. Market size and forecast

5.2. Cardiovascular disease

5.2.1. Market Size and forecast

5.3. Infectious diseases

5.3.1. Market Size and forecast

5.4. Oncology

5.4.1. Market Size and forecast

5.5. Neurological diseases

5.5.1. Market Size and forecast

5.6. Psychiatry

5.6.1. Market Size and forecast

5.7. Others

5.7.1. Market Size and forecast

Chapter: 6: GLOBAL PHARMACOGENOMICS MARKET BY END USER

6.1. Overview

6.1.1. Market size and forecast

6.2. Hospitals and Clinics

6.2.1. Market Size and forecast

6.3. Research Institutions and Academic institutes

6.3.1. Market Size and forecast

6.4. Others

6.4.1. Market Size and forecast

Chapter: 7: PHARMACOGENOMICS MARKET, BY REGION

7.1. Overview

7.1.1. Market size and forecast

7.2. North America

7.2.1. Key market trends, growth factors, and opportunities

7.2.2. North America market size and forecast, by country

7.2.2.1. U.S. market size and forecast, by technology

7.2.2.2. U.S. market size and forecast, by application

7.2.2.3. U.S. market size and forecast, by end user

7.2.2.4. Canada market size and forecast, by technology

7.2.2.5. Canada market size and forecast, by application

7.2.2.6. Canada. market size and forecast, by end user

7.2.2.7. Mexico market size and forecast, by technology

7.2.2.8. Mexico market size and forecast, by application

7.2.2.9. Mexico. market size and forecast, by end user

7.2.3. North America market size and forecast, by type

7.2.4. North America market size and forecast, by application

7.2.5. North America market size and forecast, by end user

7.3. Europe

7.3.1. Key market trends, growth factors, and opportunities

7.3.2. Europe market size and forecast, by country

7.3.2.1. Germany market size and forecast, by technology

7.3.2.2. Germany market size and forecast, by application

7.3.2.3. Germany. market size and forecast, by end user

7.3.2.4. France market size and forecast, by technology

7.3.2.5. France market size and forecast, by application

7.3.2.6. France. market size and forecast, by end user

7.3.2.7. Spain market size and forecast, by technology

7.3.2.8. Spain market size and forecast, by application

7.3.2.9. Spain. market size and forecast, by end user

7.3.2.10. Italy market size and forecast, by technology

7.3.2.11. Italy market size and forecast, by application

7.3.2.12. Italy. market size and forecast, by end user

7.3.2.13. UK market size and forecast, by technology

7.3.2.14. UK market size and forecast, by application

7.3.2.15. UK. market size and forecast, by end user

7.3.2.16. UK market size and forecast, by technology

7.3.2.17. Rest of Europe market size and forecast, by technology

7.3.2.18. Rest of Europe market size and forecast, by application

7.3.2.19. Rest of Europe. market size and forecast, by end user

7.3.3. Europe market size and forecast, by type

7.3.4. Europe market size and forecast, by application

7.3.5. Europe market size and forecast, by end user

7.4. Asia-Pacific

7.4.1. Key market trends, growth factors, and opportunities

7.4.2. Asia-Pacific market size and forecast, by country

7.4.2.1. China market size and forecast, by technology

7.4.2.2. China market size and forecast, by application

7.4.2.3. China. market size and forecast, by end user

7.4.2.4. Japan market size and forecast, by technology

7.4.2.5. Japan market size and forecast, by application

7.4.2.6. Japan. market size and forecast, by end user

7.4.2.7. India market size and forecast, by technology

7.4.2.8. India market size and forecast, by application

7.4.2.9. India market size and forecast, by end user

7.4.2.10. Rest of Asia-Pacific market size and forecast, by technology

7.4.2.11. Rest of Asia-Pacific market size and forecast, by application

7.4.2.12. Rest of Asia-Pacific. market size and forecast, by end user

7.4.3. Asia-Pacific market size and forecast, by type

7.4.4. Asia-Pacific market size and forecast, by application

7.4.5. Asia-Pacific market size and forecast, by end user

7.5. LAMEA

7.5.1. Key market trends, growth factors, and opportunities

7.5.2. LAMEA market size and forecast, by country

7.5.2.1. Latin America market size and forecast, by technology

7.5.2.2. Latin America market size and forecast, by application

7.5.2.3. Latin America market size and forecast, by end user

7.5.2.4. Middle East market size and forecast, by technology

7.5.2.5. Middle East market size and forecast, by application

7.5.2.6. Middle East. market size and forecast, by end user

7.5.2.7. Africa market size and forecast, by technology

7.5.2.8. Africa market size and forecast, by application

7.5.2.9. Africa market size and forecast, by end user

7.5.3. LAMEA market size and forecast, by type

7.5.4. LAMEA market size and forecast, by application

7.5.5. LAMEA market size and forecast, by end user

Chapter: 8: COMPANY PROFILES

8.1. Abbott Laboratories

8.1.1. Company overview

8.1.2. Company snapshot

8.1.3. Operating business segments

8.1.4. Product Portfolio

8.1.5. Business performance

8.2. Admera Health

8.2.1. Company overview

8.2.2. Company snapshot

8.2.3. Product portfolio

8.3. Dynamic DNA Laboratories

8.3.1. Company overview

8.3.2. Company snapshot

8.3.3. Operating business segments

8.3.4. Product portfolio

8.4. Empire Genomics, LLC.

8.4.1. Company overview

8.4.2. Company snapshot

8.4.3. Product portfolio

8.5. F. Hoffmann-La Roche Ltd.

8.5.1. Company overview

8.5.2. Company snapshot

8.5.3. Operating business segments

8.5.4. Product portfolio

8.5.5. Business performance

8.5.6. Key strategic moves and developments

8.6. Illumina, Inc.

8.6.1. Company overview

8.6.2. Company snapshot

8.6.3. Operating business segments

8.6.4. Product Portfolio

8.6.5. Business performance

8.7. OneOme, LLC

8.7.1. Company overview

8.7.2. Company snapshot

8.7.3. Product Portfolio

8.8. Myriad Genetics Inc.

8.8.1. Company overview

8.8.2. Company snapshot

8.8.3. Operating business segments

8.8.4. Product Portfolio

8.9. OPKO Health, Inc. (GeneDx.)

8.9.1. Company overview

8.9.2. Company snapshot

8.9.3. Operating business segments

8.9.4. Product Portfolio

8.9.5. Business performance

8.10. Thermo Fisher Scientific, Inc.

8.10.1. Company overview

8.10.2. Company snapshot

8.10.3. Operating business segments

8.10.4. Product Portfolio

8.10.5. Business performanc

LIST OF TABLES

TABLE 01. GLOBAL PHARMACOGENOMICS MARKET, BY TECHNOLOGY, 2017–2025 ($MILLION)

TABLE 02. GLOBAL PHARMACOGENOMICS MARKET, BY REGION, 2017–2025 ($MILLION)

TABLE 03. POLYMERASE CHAIN REACTION MARKET BY REGION, 2017–2025 ($MILLION)

TABLE 04. GEL ELECTROPHORESIS MARKET BY REGION, 2017–2025 ($MILLION)

TABLE 05. MASS SPECTROMETRY MARKET BY REGION, 2017–2025 ($MILLION)

TABLE 06. MICROARRAY MARKET BY REGION, 2017–2025 ($MILLION)

TABLE 07. OTHERS MARKET BY REGION, 2017–2025 ($MILLION)

TABLE 08. GLOBAL PHARMACOGENOMICS MARKET, BY REGION, 2018–2025 ($MILLION)

TABLE 09. GLOBAL CARDIOVASCULAR DISEASE MARKET, BY REGION, 2018–2025 ($MILLION)

TABLE 10. GLOBAL INFECTIOUS DISEASES MARKET, BY REGION, 2018–2025 ($MILLION)

TABLE 11. ONCOLOGY MARKET, BY REGION, 2018–2025 ($MILLION)

TABLE 12. NEUROLOGICAL DISEASES MARKET, BY REGION, 2018–2025 ($MILLION)

TABLE 13. PSYCHIATRY MARKET, BY REGION, 2018–2025 ($MILLION)

TABLE 14. OTHERS MARKET, BY REGION, 2018–2025 ($MILLION)

TABLE 15. GLOBAL PHARMACOGENOMICS MARKET REVENUE, BY REGION, 2017–2025 ($MILLION)

TABLE 16. HOSPITALS AND CLINICS MARKET, BY REGION, 2017–2025 ($MILLION)

TABLE 17. RESEARCH INSTITUTIONS AND ACADEMIC INSTITUTES MARKET, BY REGION, 2017–2025 ($MILLION)

TABLE 18. OTHERS MARKET, BY REGION, 2017–2025 ($MILLION)

TABLE 19. PHARMACOGENOMICS MARKET REVENUE, BY REGION, 2017–2025 ($MILLION)

TABLE 20. NORTH AMERICA PHARMACOGENOMICS MARKET, BY COUNTRY, 2017–2025 ($MILLION)

TABLE 21. U.S. PHARMACOGENOMICS MARKET, BY TECHNOLOGY, 2017–2025 ($MILLION)

TABLE 22. U.S. PHARMACOGENOMICS MARKET, BY APPLICATION, 2017–2025 ($MILLION)

TABLE 23. U.S. PHARMACOGENOMICS MARKET, BY END USER, 2017–2025 ($MILLION)

TABLE 24. CANADA PHARMACOGENOMICS MARKET, BY TECHNOLOGY, 2017–2025 ($MILLION)

TABLE 25. CANADA PHARMACOGENOMICS MARKET, BY APPLICATION, 2017–2025 ($MILLION)

TABLE 26. CANADA PHARMACOGENOMICS MARKET, BY END USER, 2017–2025 ($MILLION)

TABLE 27. MEXICO PHARMACOGENOMICS MARKET, BY TECHNOLOGY, 2017–2025 ($MILLION)

TABLE 28. MEXICO PHARMACOGENOMICS MARKET, BY APPLICATION, 2017–2025 ($MILLION)

TABLE 29. MEXICO PHARMACOGENOMICS MARKET, BY END USER, 2017–2025 ($MILLION)

TABLE 30. NORTH AMERICA PHARMACOGENOMICS MARKET, BY TECHNOLOGY, 2017–2025 ($MILLION)

TABLE 31. NORTH AMERICA PHARMACOGENOMICS MARKET, BY APPLICATION, 2017–2025 ($MILLION)

TABLE 32. NORTH AMERICA PHARMACOGENOMICS MARKET, BY END USER, 2017–2025 ($MILLION)

TABLE 33. EUROPE PHARMACOGENOMICS MARKET, BY COUNTRY, 2017–2025 ($MILLION)

TABLE 34. GERMANY PHARMACOGENOMICS MARKET, BY TECHNOLOGY, 2017–2025 ($MILLION)

TABLE 35. GERMANY PHARMACOGENOMICS MARKET, BY APPLICATION, 2017–2025 ($MILLION)

TABLE 36. GERMANY PHARMACOGENOMICS MARKET, BY END USER, 2017–2025 ($MILLION)

TABLE 37. FRANCE PHARMACOGENOMICS MARKET, BY TECHNOLOGY, 2017–2025 ($MILLION)

TABLE 38. FRANCE PHARMACOGENOMICS MARKET, BY APPLICATION, 2017–2025 ($MILLION)

TABLE 39. FRANCE PHARMACOGENOMICS MARKET, BY END USER, 2017–2025 ($MILLION)

TABLE 40. SPAIN PHARMACOGENOMICS MARKET, BY TECHNOLOGY, 2017–2025 ($MILLION)

TABLE 41. SPAIN PHARMACOGENOMICS MARKET, BY APPLICATION, 2017–2025 ($MILLION)

TABLE 42. SPAIN PHARMACOGENOMICS MARKET, BY END USER, 2017–2025 ($MILLION)

TABLE 43. ITALY PHARMACOGENOMICS MARKET, BY TECHNOLOGY, 2017–2025 ($MILLION)

TABLE 44. ITALY PHARMACOGENOMICS MARKET, BY APPLICATION, 2017–2025 ($MILLION)

TABLE 45. ITALY PHARMACOGENOMICS MARKET, BY END USER, 2017–2025 ($MILLION)

TABLE 46. UK PHARMACOGENOMICS MARKET, BY TECHNOLOGY, 2017–2025 ($MILLION)

TABLE 47. UK PHARMACOGENOMICS MARKET, BY APPLICATION, 2017–2025 ($MILLION)

TABLE 48. UK PHARMACOGENOMICS MARKET, BY END USER, 2017–2025 ($MILLION)

TABLE 49. UK PHARMACOGENOMICS MARKET, BY TECHNOLOGY, 2017–2025 ($MILLION)

TABLE 50. REST OF EUROPE PHARMACOGENOMICS MARKET, BY TECHNOLOGY, 2017–2025 ($MILLION)

TABLE 51. REST OF EUROPE PHARMACOGENOMICS MARKET, BY APPLICATION, 2017–2025 ($MILLION)

TABLE 52. REST OF EUROPE PHARMACOGENOMICS MARKET, BY END USER, 2017–2025 ($MILLION)

TABLE 53. EUROPE PHARMACOGENOMICS MARKET, BY TYPE, 2017–2025 ($MILLION)

TABLE 54. EUROPE PHARMACOGENOMICS MARKET, BY APPLICATION, 2017–2025 ($MILLION)

TABLE 55. EUROPE PHARMACOGENOMICS MARKET, BY END USER, 2017–2025 ($MILLION)

TABLE 56. ASIA-PACIFIC PHARMACOGENOMICS MARKET, BY COUNTRY, 2017–2025 ($MILLION)

TABLE 57. CHINA PHARMACOGENOMICS MARKET, BY TECHNOLOGY, 2017–2025 ($MILLION)

TABLE 58. CHINA PHARMACOGENOMICS MARKET, BY APPLICATION, 2017–2025 ($MILLION)

TABLE 59. CHINA PHARMACOGENOMICS MARKET, BY END USER, 2017–2025 ($MILLION)

TABLE 60. JAPAN PHARMACOGENOMICS MARKET, BY TECHNOLOGY, 2017–2025 ($MILLION)

TABLE 61. JAPAN PHARMACOGENOMICS MARKET, BY APPLICATION, 2017–2025 ($MILLION)

TABLE 62. JAPAN PHARMACOGENOMICS MARKET, BY END USER, 2017–2025 ($MILLION)

TABLE 63. INDIA PHARMACOGENOMICS MARKET, BY TECHNOLOGY, 2017–2025 ($MILLION)

TABLE 64. INDIA PHARMACOGENOMICS MARKET, BY APPLICATION, 2017–2025 ($MILLION)

TABLE 65. INDIA PHARMACOGENOMICS MARKET, BY END USER, 2017–2025 ($MILLION)

TABLE 66. REST OF ASIA-PACIFIC PHARMACOGENOMICS MARKET, BY TECHNOLOGY, 2017–2025 ($MILLION)

TABLE 67. REST OF ASIA-PACIFIC PHARMACOGENOMICS MARKET, BY APPLICATION, 2017–2025 ($MILLION)

TABLE 68. REST OF ASIA-PACIFIC PHARMACOGENOMICS MARKET, BY END USER, 2017–2025 ($MILLION)

TABLE 69. ASIA-PACIFIC PHARMACOGENOMICS MARKET, BY TYPE, 2017–2025 ($MILLION)

TABLE 70. ASIA-PACIFIC PHARMACOGENOMICS MARKET, BY APPLICATION, 2017–2025 ($MILLION)

TABLE 71. ASIA-PACIFIC PHARMACOGENOMICS MARKET, BY END USER, 2017–2025 ($MILLION)

TABLE 72. LAMEA PHARMACOGENOMICS MARKET, BY COUNTRY, 2017–2025 ($MILLION)

TABLE 73. LATIN AMERICA PHARMACOGENOMICS MARKET, BY TECHNOLOGY, 2017–2025 ($MILLION)

TABLE 74. LATIN AMERICA PHARMACOGENOMICS MARKET, BY APPLICATION, 2017–2025 ($MILLION)

TABLE 75. LATIN AMERICA PHARMACOGENOMICS MARKET, BY END USER, 2017–2025 ($MILLION)

TABLE 76. MIDDLE EAST PHARMACOGENOMICS MARKET, BY TECHNOLOGY, 2017–2025 ($MILLION)

TABLE 77. MIDDLE EAST PHARMACOGENOMICS MARKET, BY APPLICATION, 2017–2025 ($MILLION)

TABLE 78. MIDDLE EAST PHARMACOGENOMICS MARKET, BY END USER, 2017–2025 ($MILLION)

TABLE 79. AFRICA PHARMACOGENOMICS MARKET, BY TECHNOLOGY, 2017–2025 ($MILLION)

TABLE 80. AFRICA PHARMACOGENOMICS MARKET, BY APPLICATION, 2017–2025 ($MILLION)

TABLE 81. AFRICA PHARMACOGENOMICS MARKET, BY END USER, 2017–2025 ($MILLION)

TABLE 82. LAMEA PHARMACOGENOMICS MARKET, BY TYPE, 2017–2025 ($MILLION)

TABLE 83. LAMEA PHARMACOGENOMICS MARKET, BY APPLICATION, 2017–2025 ($MILLION)

TABLE 84. LAMEA PHARMACOGENOMICS MARKET, BY END USER, 2017–2025 ($MILLION)

TABLE 85. ABBOTT: COMPANY SNAPSHOT

TABLE 86. ABBOTT: OPERATING SEGMENTS

TABLE 87. ABBOTT: PRODUCT PORTFOLIO

TABLE 88. ADMERA HEALTH: COMPANY SNAPSHOT

TABLE 89. ADMERA HEALTH: PRODUCT PORTFOLIO

TABLE 90. DYNAMIC DNA LABORATORIES: COMPANY SNAPSHOT

TABLE 91. DYNAMIC DNA LABS: OPERATING SEGMENTS

TABLE 92. DYNAMIC DNA LABS: PRODUCT PORTFOLIO

TABLE 93. EMPIRE GENOMICS: COMPANY SNAPSHOT

TABLE 94. EMPIRE GENOMICS: PRODUCT PORTFOLIO

TABLE 95. F. HOFFMANN-LA ROCHE: COMPANY SNAPSHOT

TABLE 96. F. HOFFMANN-LA ROCHE: OPERATING SEGMENTS

TABLE 97. F. HOFFMANN-LA ROCHE: PRODUCT PORTFOLIO

TABLE 98. ILLUMINA: COMPANY SNAPSHOT

TABLE 99. ILLUMINA: OPERATING SEGMENTS

TABLE 100. ILLUMINA: PRODUCT PORTFOLIO

TABLE 101. ONEOME, LLC: COMPANY SNAPSHOT

TABLE 102. ONEOME, LLC: PRODUCT PORTFOLIO

TABLE 103. MYRIAD GENETICS INC.: COMPANY SNAPSHOT

TABLE 104. MYRIAD GENETICS: PRODUCT PORTFOLIO

TABLE 105. OPKO: COMPANY SNAPSHOT

TABLE 106. OPKO: OPERATING SEGMENTS

TABLE 107. OPKO: PRODUCT PORTFOLIO

TABLE 108. THERMO FISHER SCIENTIFIC: COMPANY SNAPSHOT

TABLE 109. THERMO FISHER SCIENTIFIC: OPERATING SEGMENTS

TABLE 110. THERMO FISHER SCIENTIFIC: PRODUCT PORTFOLIO LIST OF FIGURES

FIGURE 01. SEGMENTATION OF GLOBAL PHARMACOGENOMICS MARKET

FIGURE 02. TOP INVESTMENT POCKETS IN THE GLOBAL ENTERPRISE CONTENT MANAGEMENT MARKET

FIGURE 03. LOW BARGAINING POWER OF SUPPLIERS

FIGURE 04. MODERATE BARGAINING POWER OF BUYERS

FIGURE 05. MODERATE THREAT OF SUBSTITUTION

FIGURE 06. MODERATE THREAT OF NEW ENTRANT

FIGURE 07. HIGH COMPETITIVE RIVALRY

FIGURE 08. TOP PLAYER POSITIONING, 2017

FIGURE 09. ABBOTT: NET SALES, 2015–2017 ($MILLION)

FIGURE 10. ABBOTT: NET SALES SHARE, BY OPERATING SEGMENT, 2017 (%)

FIGURE 11. ABBOTT: NET SALES SHARE, BY GEOGRAPHY, 2017 (%)

FIGURE 12. F. HOFFMANN-LA ROCHE: NET SALES, 2015–2017 ($MILLION)

FIGURE 13. F. HOFFMANN-LA ROCHE: REVENUE SHARE BY SEGMENT, 2017 (%)

FIGURE 14. ILLUMINA: REVENUE, 2015–2017 ($MILLION)

FIGURE 15. ILLUMINA: REVENUE SHARE, BY OPERATING SEGMENT, 2017 (%)

FIGURE 16. ILLUMINA: REVENUE SHARE, BY GEOGRAPHY, 2017 (%)

FIGURE 17. OPKO: REVENUE, 2015–2017 ($MILLION)

FIGURE 18. OPKO: REVENUE SHARE, BY SEGMENT, 2017 (%)

FIGURE 19. OPKO: REVENUE SHARE, BY GEOGRAPHY, 2017 (%)

FIGURE 20. THERMO FISHER SCIENTIFIC: REVENUE, 2015–2017 ($MILLION)

FIGURE 21. THERMO FISHER SCIENTIFIC: REVENUE SHARE, BY SEGMENT, 2017 (%)

FIGURE 22. THERMO FISHER SCIENTIFIC: REVENUE SHARE, BY GEOGRAPHY, 2017 (%